ATE226091T1 - Mikrokapseln mit gesteuerter freigabe sowie deren verwendung zur stimulierung des nervenfaserwachstums - Google Patents

Mikrokapseln mit gesteuerter freigabe sowie deren verwendung zur stimulierung des nervenfaserwachstums

Info

Publication number
ATE226091T1
ATE226091T1 AT91910707T AT91910707T ATE226091T1 AT E226091 T1 ATE226091 T1 AT E226091T1 AT 91910707 T AT91910707 T AT 91910707T AT 91910707 T AT91910707 T AT 91910707T AT E226091 T1 ATE226091 T1 AT E226091T1
Authority
AT
Austria
Prior art keywords
nerve fiber
controlled release
fiber growth
release microcapsules
stimulating nerve
Prior art date
Application number
AT91910707T
Other languages
English (en)
Inventor
Thomas R Tice
Deborah L Dillon
David W Mason
Original Assignee
Southern Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Southern Res Inst filed Critical Southern Res Inst
Application granted granted Critical
Publication of ATE226091T1 publication Critical patent/ATE226091T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT91910707T 1990-05-16 1991-05-14 Mikrokapseln mit gesteuerter freigabe sowie deren verwendung zur stimulierung des nervenfaserwachstums ATE226091T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52538390A 1990-05-16 1990-05-16
PCT/US1991/003356 WO1991017772A1 (en) 1990-05-16 1991-05-14 Controlled release dopamine and its use to stimulate nerve fiber growth

Publications (1)

Publication Number Publication Date
ATE226091T1 true ATE226091T1 (de) 2002-11-15

Family

ID=24093026

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91910707T ATE226091T1 (de) 1990-05-16 1991-05-14 Mikrokapseln mit gesteuerter freigabe sowie deren verwendung zur stimulierung des nervenfaserwachstums

Country Status (8)

Country Link
US (1) US5360610A (de)
EP (1) EP0528978B1 (de)
JP (2) JP3359919B2 (de)
AT (1) ATE226091T1 (de)
DE (1) DE69133136T2 (de)
DK (1) DK0528978T3 (de)
ES (1) ES2185615T3 (de)
WO (1) WO1991017772A1 (de)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309669B1 (en) 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
US6217911B1 (en) 1995-05-22 2001-04-17 The United States Of America As Represented By The Secretary Of The Army sustained release non-steroidal, anti-inflammatory and lidocaine PLGA microspheres
US5693343A (en) 1984-03-16 1997-12-02 The United States Of America As Represented By The Secretary Of The Army Microparticle carriers of maximal uptake capacity by both M cells and non-M cells
US6410056B1 (en) 1984-03-16 2002-06-25 The United States Of America As Represented By The Secretary Of The Army Chemotherapeutic treatment of bacterial infections with an antibiotic encapsulated within a biodegradable polymeric matrix
USRE40786E1 (en) 1984-03-16 2009-06-23 The United States Of America As Represented By The Secretary Of The Army Vaccines against intracellular pathogens using antigens encapsulated within biodegradable-biocompatible microspheres
US5871472A (en) * 1987-11-17 1999-02-16 Brown University Research Foundation Planting devices for the focal release of neuroinhibitory compounds
US6517859B1 (en) 1990-05-16 2003-02-11 Southern Research Institute Microcapsules for administration of neuroactive agents
US5618531A (en) 1990-10-19 1997-04-08 New York University Method for increasing the viability of cells which are administered to the brain or spinal cord
AU8303691A (en) 1991-04-24 1992-12-21 United States Of America, As Represented By The Secretary Of The Army, The Oral-intestinal vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres
DE69331387T2 (de) * 1992-09-10 2002-08-22 Childrens Medical Center Biodegradierbare polymeren matrizen mit verzoegerter freisetzung von lokalanaesthetika
US5700485A (en) * 1992-09-10 1997-12-23 Children's Medical Center Corporation Prolonged nerve blockade by the combination of local anesthetic and glucocorticoid
US5383873A (en) * 1992-12-09 1995-01-24 Regents Of The University Of Minnesota Smooth muscle chemical pacemaker
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US6939546B2 (en) 1993-05-21 2005-09-06 The United States Of America As Represented By The Secretary Of The Army Model for testing immunogenicity of peptides
ATE288270T1 (de) * 1993-11-19 2005-02-15 Janssen Pharmaceutica Nv Mikroverkapselte 1,2-benzazole
US5962427A (en) 1994-02-18 1999-10-05 The Regent Of The University Of Michigan In vivo gene transfer methods for wound healing
US5942496A (en) 1994-02-18 1999-08-24 The Regent Of The University Of Michigan Methods and compositions for multiple gene transfer into bone cells
US5763416A (en) 1994-02-18 1998-06-09 The Regent Of The University Of Michigan Gene transfer into bone cells and tissues
US6074840A (en) 1994-02-18 2000-06-13 The Regents Of The University Of Michigan Recombinant production of latent TGF-beta binding protein-3 (LTBP-3)
US6551618B2 (en) 1994-03-15 2003-04-22 University Of Birmingham Compositions and methods for delivery of agents for neuronal regeneration and survival
US5604198A (en) * 1994-05-12 1997-02-18 Poduslo; Joseph F. Method to enhance permeability of the blood/brain blood/nerve barriers to therapeutic agents
US6447796B1 (en) 1994-05-16 2002-09-10 The United States Of America As Represented By The Secretary Of The Army Sustained release hydrophobic bioactive PLGA microspheres
US6855331B2 (en) 1994-05-16 2005-02-15 The United States Of America As Represented By The Secretary Of The Army Sustained release hydrophobic bioactive PLGA microspheres
US7033608B1 (en) 1995-05-22 2006-04-25 The United States Of America As Represented By The Secretary Of The Army “Burst-free” sustained release poly-(lactide/glycolide) microspheres
US6902743B1 (en) 1995-05-22 2005-06-07 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive material(s) encapuslated within a biodegradable-bio-compatable polymeric matrix
US5942241A (en) 1995-06-09 1999-08-24 Euro-Celtique, S.A. Formulations and methods for providing prolonged local anesthesia
WO1998008464A1 (en) 1996-08-29 1998-03-05 Advanced Research & Technology Institute Novel pharmacotherapeutic process and composition for central nervous system disorders
DK0925067T3 (da) 1996-09-16 2004-05-03 Purdue Research Foundation Graft fra submucosavæv til reparation af neurologisk væv
CA2296056A1 (en) * 1997-07-10 1999-01-21 Keith Baker Methods for universally distributing therapeutic agents to the brain
ES2320603T3 (es) 1997-07-30 2009-05-25 Emory University Sistemas de expresion, vectores, adn, proteinas de mineralizacion osea novedosos.
US7923250B2 (en) 1997-07-30 2011-04-12 Warsaw Orthopedic, Inc. Methods of expressing LIM mineralization protein in non-osseous cells
EP1079967A4 (de) 1998-04-13 2003-07-23 Luminex Corp Flüssige markierung mit fluorezierenden mikropartikeln
OA11728A (en) * 1998-12-16 2005-02-01 Aventis Pharma Inc Biodegradable polymer encapsulated serotonin receptor antagonist and method for preparing the same.
US6455526B1 (en) 1998-12-16 2002-09-24 Aventis Pharmaceuticals, Inc. Biodegradable polymer encapsulated pharmaceutical compositions and method for preparing the same
US6458387B1 (en) * 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
WO2001080830A2 (en) * 2000-04-21 2001-11-01 Advanced Research And Technology Institute, Inc. Pharmacotherapeutic process and composition for central nervous system disorders
DE60138641D1 (de) 2000-10-27 2009-06-18 Baxter Healthcare Sa Herstellung von mikrokügelchen
US20030064033A1 (en) * 2001-08-16 2003-04-03 Brown Larry R. Propellant-based microparticle formulations
US6488952B1 (en) * 2001-08-28 2002-12-03 John P. Kennedy Semisolid therapeutic delivery system and combination semisolid, multiparticulate, therapeutic delivery system
CA2518667C (en) 2003-03-14 2011-07-19 The Trustees Of Columbia University In The City Of New York Systems and methods of blood-based therapies having a microfluidic membraneless exchange device
US20060076295A1 (en) 2004-03-15 2006-04-13 The Trustees Of Columbia University In The City Of New York Systems and methods of blood-based therapies having a microfluidic membraneless exchange device
US8075919B2 (en) * 2003-07-18 2011-12-13 Baxter International Inc. Methods for fabrication, uses and compositions of small spherical particles prepared by controlled phase separation
US20050142205A1 (en) * 2003-07-18 2005-06-30 Julia Rashba-Step Methods for encapsulating small spherical particles prepared by controlled phase separation
US20070092452A1 (en) * 2003-07-18 2007-04-26 Julia Rashba-Step Methods for fabrication, uses, compositions of inhalable spherical particles
WO2005009375A2 (en) * 2003-07-22 2005-02-03 Baxter International Inc. Small spherical particles of low molecular weight organic molecules and methods of preparation and use thereof
US7309232B2 (en) * 2003-10-10 2007-12-18 Dentigenix Inc. Methods for treating dental conditions using tissue scaffolds
US8728525B2 (en) 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
EP1765294B1 (de) 2004-05-12 2008-09-24 Baxter International Inc. Nukleinsäure-mikrokügelchen, ihre herstellung und abgabe
US7884085B2 (en) 2004-05-12 2011-02-08 Baxter International Inc. Delivery of AS-oligonucleotide microspheres to induce dendritic cell tolerance for the treatment of autoimmune type 1 diabetes
CN103393601A (zh) 2004-05-12 2013-11-20 巴克斯特国际公司 含有蛋白并在高浓度蛋白下显示可注射性的微球体
WO2006047299A2 (en) * 2004-10-22 2006-05-04 University Of Florida Research Foundation, Inc. Organotypic slice cultures and uses thereof
US20060228420A1 (en) * 2005-03-15 2006-10-12 Queen Mary & Westfield College Pharmaceutical compositions comprising microparticles for delivery into neurons
CA2652173A1 (en) 2006-05-22 2007-11-29 Edward F. Leonard Systems and methods of microfluidic membraneless exchange using filtration of extraction fluid outlet streams
WO2008006064A2 (en) * 2006-07-07 2008-01-10 Georgia Tech Research Corporation Biomimetic polymers and uses thereof
AU2007281737B2 (en) 2006-08-04 2013-09-19 Baxter Healthcare S.A. Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
CA2702340C (en) 2006-10-12 2014-12-16 The University Of Queensland Compositions and methods for modulating immune responses
CN100462105C (zh) * 2006-10-19 2009-02-18 中国人民解放军第四军医大学 一种重组合神经替代物的制备方法
CN101686939B (zh) 2007-04-17 2013-03-27 巴克斯特国际公司 用于肺部投送的核酸微粒
EP2249899A4 (de) 2008-02-04 2011-05-11 Univ Columbia Fluidtrennvorrichtungen, -systeme und -verfahren
AU2009237577B2 (en) 2008-04-18 2014-06-05 Baxter Healthcare Sa Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
EP2306991B1 (de) * 2008-06-27 2019-12-25 Tepha, Inc. Verbesserte injektionsabgabe von mikroteilchen und zusammensetzungen dafür
EP2326336B1 (de) 2008-07-30 2015-05-13 Mesynthes Limited Gewebegerüste aus extrazellulärer vormagenmatrix
US8323615B2 (en) 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing multi-phasic dispersions
US8367427B2 (en) 2008-08-20 2013-02-05 Baxter International Inc. Methods of processing compositions containing microparticles
US8323685B2 (en) * 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing compositions containing microparticles
EP2308478A1 (de) * 2009-10-06 2011-04-13 Abbott GmbH & Co. KG Abgabesystem zur verzögerten Freisetzung von Calciumkanalblocker Arzneistoffen
BR112013010926A2 (pt) 2010-11-01 2016-08-23 Univ Technology Sidney agentes imunomoduladores e seus usos
US10695406B2 (en) 2014-05-27 2020-06-30 The University Of Queensland Modulation of cellular stress using a B-cell oxidative and/or endoplasmic reticulum stress inhibitor and a targeting agent
KR102418503B1 (ko) * 2020-11-27 2022-07-07 주식회사 헤리노브 탄소섬유를 사용한 파이프 제조방법 및 이를 통해 제조된 파이프

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
JPS6048923A (ja) * 1983-08-25 1985-03-16 Mitsui Toatsu Chem Inc 微小粒子の製造方法
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US4962091A (en) * 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
US4832686A (en) * 1986-06-24 1989-05-23 Anderson Mark E Method for administering interleukin-2
JPS63122620A (ja) * 1986-11-12 1988-05-26 Sanraku Inc ポリ乳酸マイクロスフエア及びその製造方法
US4883666A (en) * 1987-04-29 1989-11-28 Massachusetts Institute Of Technology Controlled drug delivery system for treatment of neural disorders
ES2058923T3 (es) * 1989-06-21 1994-11-01 Univ Brown Res Found Sistema para terapia neurologica.
CH679207A5 (de) * 1989-07-28 1992-01-15 Debiopharm Sa
JP3187410B2 (ja) * 1989-08-10 2001-07-11 住友製薬株式会社 脳内投与用徐放性製剤

Also Published As

Publication number Publication date
JP3359919B2 (ja) 2002-12-24
JP2003012506A (ja) 2003-01-15
DE69133136D1 (de) 2002-11-21
US5360610A (en) 1994-11-01
DK0528978T3 (da) 2003-02-17
DE69133136T2 (de) 2003-06-18
ES2185615T3 (es) 2003-05-01
WO1991017772A1 (en) 1991-11-28
JP4044366B2 (ja) 2008-02-06
JPH05507486A (ja) 1993-10-28
EP0528978A4 (en) 1993-06-23
EP0528978A1 (de) 1993-03-03
EP0528978B1 (de) 2002-10-16

Similar Documents

Publication Publication Date Title
DE69133136D1 (de) Mikrokapseln mit gesteuerter freigabe sowie deren verwendung zur stimulierung des nervenfaserwachstums
DK0767634T3 (da) Mikrokapsler til administration af neuroaktive midler
DE69203596D1 (de) Biologisch abbaubare und biologisch absorbierbare führungskanäle zur verwendung in der behandlung und regenerierung von nerven.
DE69529054D1 (de) System zur gezielten wirkstoffzufuhr, verfahren zu seiner herstellung und verwendung
ATE129892T1 (de) Depotimplantat mit gesteuerter wirkstoffabgabe zur behandlung von krankheiten des nervensystems.
DK0862416T3 (da) Ikke-polymert indgivelsessystem med forhalet frigørelse
ATE286384T1 (de) Formulierung mit verzögerter freisetzung enthaltend kollagen und glykosaminoglykan
EP0322319A3 (en) Composition comprising biodegradable ocular implants
GB9014052D0 (en) Bioceramic system for delivery of a bioactive compound
ES2133413T3 (es) Gel de lecitina inyectable.
DE69530919D1 (de) Beigeordnetes polymersystem zur verwendung mit einer medizinischen vorrichtung
DE69224456D1 (de) Biologisch abbaubare Polymerzusammensetzung
PT97446A (pt) Processo para a preparacao de um derivado de tienobenzodiazepina, util como produto farmaceutico
PT777483E (pt) Metodos e meio para administrar farmacos
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
EP0660705A4 (de) Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin.
ATE94069T1 (de) Verwendung von physiologisch wirksamen substanzen zur herstellung von medikamenten fuer gehirn- und nervenerkrankungen.
ATE89485T1 (de) Neurologisches therapiesystem.
MX9204303A (es) Factor regulador del crecimiento de osteoclasto.
DE69621243D1 (de) Verwendung von bradykininantagonisten zur induzierung oder stimulation des haarwachstums und/oder zur verlangsamung des haarausfalls
ATE149361T1 (de) Nerveneinpflanzungssystem
MX9701187A (es) Nuevas lactamas naftofusionadas n-substituidas.
DE59010513D1 (de) Medikamente zur tumortherapie mit kontrolliertem und reguliertem immunsystem sowie verwendung der einzelsubstanzen zur kombinierten therapie
Gonzalez-Lima Activation of substantia gelatinosa by midbrain reticular stimulation demonstrated with 2-deoxyglucose in the rat spinal cord
DK0426098T3 (da) Fremstilling af et lægemiddel til behandling af hyperphosphatæmisk status

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0528978

Country of ref document: EP

REN Ceased due to non-payment of the annual fee